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Abstract Recruitment and retention of circulating progen-
itor cells at the site of injured or ischemic tissues facilitates
adult neo-vascularization. We hypothesized that cell thera-
py could modulate local neo-vascularization through the
vascular endothelial growth factor (VEGF)/stromal cell-
derived factor-1 (SDF-1) axis and by paracrine effects on
local endothelial cells. We isolated from rat bone marrow a
subset of multipotent adult progenitor cell-derived progen-
itor cells (MDPC). In vitro, MDPCs secreted multiple
cytokines related to inflammation and angiogenesis, includ-
ing monocyte chemotactic protein-1, SDF-1, basic fibro-
blast growth factor, and VEGF, and expressed the
chemokine receptors CXCR4 and VEGFR1. To investigate
in vivo properties, we transplanted MDPCs into the
ischemic hind limbs of rats. Elevated levels of the chemo-
kine SDF-1 and colocalization of CD11b+ cells marked the
initial phase of tissue remodeling after cell transplantation.
Prolonged engraftment was observed in the adventitial–
medial border region of arterioles of ischemic muscles.
However, engrafted cells did not differentiate into endothe-
lial or smooth muscle cells. Limb perfusion normalized 4
weeks after cell injection. Inhibition of SDF-1 reduced the
engraftment of transplanted cells and decreased endothelial
cell proliferation. These findings suggest a two-stage model
whereby transplanted MDPCs modulate wound repair
through recruitment of inflammatory cells to ischemic
tissue. This is an important potential mechanism for cell
transplantation, in addition to the direct modulation of local
vascular cells through paracrine mechanisms.
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Introduction
Bone marrow-derived cells, including endothelial progeni-
tor cells [1], hematopoietic stem cells [2], and mesenchymal
stromal cells (MSCs) [3], may have the potential to
differentiate into cellular components of the vasculature
and increase the perfusion of ischemic organs. Recent
clinical trials have shown improvement of cardiac function
after infusion of bone marrow-derived cells [4, 5].
However, comparable studies have failed to demonstrate
improvement of cardiac function [6]. It is crucial that more
studies are performed to understand the mechanism of
cardiovascular repair.
The transplantation of cell types capable of multilineage
differentiation to restore the multiple cell types required to
improve function in a diseased organ has inherent appeal.
Nonembryonic multipotent and/or pluripotent progenitor
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cell populations have recently been cultured from bone
marrow, muscle, and umbilical cord blood [7–10]. These
cells all exhibit substantial replicative potential and are
capable of differentiation into various cell types belonging
to different embryonic germ layers in vitro. These progen-
itor cells may be beneficial in certain disease models,
including myocardial infarction [10]. Multipotent adult
progenitor cells (MAPCs) are an example of a pluripotent
progenitor population which can be cultured from the adult
bone marrow of humans, mice, and rats [7].
Originally, it was suggested that bonemarrow-derived cells
differentiate into vascular cells that integrate into new blood
vessels [1]. However, the level of engraftment is often
minimal or absent despite significant improvements in
perfusion [11]. Several alternative mechanisms to cell
differentiation have been proposed. These include cell fusion
[12], angiogenic growth factor delivery [13], and the
modulation of endogenous stem or progenitor cell function
by the release of the stem cell-homing cytokine stromal cell-
derived factor-1 (SDF-1) [14–16]. However, any mechanism
of engraftment and differentiation is likely to be a complex
process with interactions between the transplanted cells and
host physiological signals. Evidence suggests that vascular
endothelial growth factor (VEGF) may mediate this process
by initiating a cascade of events including the local release of
SDF-1. VEGF is known to recruit bone marrow-derived
inflammatory cells to ischemic vessels, with SDF-1, then
facilitating their retention via the chemokine receptor
CXCR4 [17, 18]. Although it is not clear whether bone
marrow-derived cells acquire an endothelial cell phenotype,
evidence suggests that recruited bone marrow-derived cells
secrete multiple factors that ultimately induce the prolifera-
tion of local endothelial cells and angiogenesis.
In this study, we explored two possible mechanisms that
may lead to improved tissue perfusion. First is the ability of
multipotent progenitor cells to regenerate vasculature.
Second is the role of paracrine effects on vascular
remodeling. Bone marrow-derived cells were cultured
under MAPC conditions and displayed in vitro properties
similar to MAPCs. We named these cells MAPC-derived
progenitor cells or MDPCs. When transplanted into a rat
ischemic hind limb model, MDPCs engrafted selectively
into the adventitial–medial border region of arterioles.
Although engrafted cells did not differentiate into endothe-
lial or vascular smooth muscle cells, we observed an
enhanced activation of the VEGF/SDF-1 system that
resulted in homing and recruitment of CD11b+ myeloid
cells. Inhibition of SDF-1/CXCR4 function decreased the
engraftment of transplanted MDPCs and endothelial cell
proliferation. We propose that, through paracrine mecha-
nisms, MDPC transplantation affects tissue remodeling and
increases tissue perfusion through modulation of the local
immune response. The VEGF/SDF-1 system appears to




12–14-week-old female inbred Fisher 344 rats (Harlan,
Indiana, USA) underwent femoral artery excision to induce
chronic limb-threatening ischemia and served as recipients
for cell transplantation. Assessment of perfusion data was
blinded. All experiments were conducted according to the
guidelines of the Animal Care and Use Committee of the
National Heart, Lung, and Blood Institute and the guide for
the Care and Use of Laboratory Animals published by the
US National Institutes of Health (NIH Publication no. 85-
23, revised 1996).
Isolation of MDPCs
MDPCs were isolated from 8-week-old male Fisher 344
rats and cultured based on protocols previously established
for MAPCs [7]. Briefly, bone marrow was harvested and
cultured in T175 polystyrene culture flasks coated with
10 ng/ml fibronectin (Sigma-Aldrich, St Louis, MO, USA)
in basal media consisting of 60%Dulbecco’s modified Eagle’s
medium (low glucose; Gibco, Carlsbad, CA, USA), 40%
MCDB 201 (Sigma-Aldrich), with 1× insulin–transferrin–
selenium, 1× linoleic acid–bovine serum albumin (BSA),
0.5 μM dexamethasone, 0.1 mM ascorbic acid 2-phosphate,
100 U penicillin–streptomycin (all Sigma-Aldrich), supple-
mented with 10 ng/ml platelet-derived growth factor
(PDGF)-BB (R&D, Minneapolis, MN, USA), 10 ng/ml
epidermal growth factor (Sigma-Aldrich), 103 U/ml leuko-
cyte inhibitory factor (Chemicon, Temecula, CA, USA), and
2% fetal bovine serum (Hyclone, Logan, UT, USA). After 2
days, nonadherent cells were discarded, and media were
subsequently changed every 48–72 h. Colonies of pro-
liferating cells were harvested after 7 days with trypsin/
ethylenediamine tetraacetic acid (EDTA) and recultured at a
density of 200 cells per cm2. Cells were maintained at low
density by being split every 48–72 h. At each passage, cells
were enumerated with a hemocytometer. A single-cell cloning
step was not undertaken. To enable identification of trans-
planted cells, MDPCs were transduced with a retrovirus
carrying the LacZ plasmid pCL-MFG-LacZ (Imgenex, San
Diego, CA, USA).
Flow cytometry
MDPCs were collected with trypsin/EDTA and washed
with fluorescence-activated cell sorting (FACS) wash
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(phosphate-buffered saline [PBS], 2 mM EDTA, and 0.5%
BSA) and stained with the following labeled antibodies:
anti-CD90 PE (clone PX-7), anti-CD44 fluorescein iso-
thiocyanate (FITC; clone OX-49), anti-major histocom-
patibility complex (MHC) class I PE (clone OX-18),
anti-MHC class II PE (clone OX-6), anti-CD45 PE (clone
OX-1), and PE and FITC isotype controls (all BD Bio-
sciences, San Diego, CA, USA). The following unlabeled
antibodies were also used: anti-CXCR4 (LS-C6307; Life-
Span BioSciences, Seattle, WA, USA), anti-VEGFR1
(ab2350; Abcam, Hartford, CT, USA), anti-CD73 (clone
5F/B9; BD Biosciences), and corresponding unlabeled
isotype controls. Secondary staining of unlabeled anti-
bodies and isotypes was performed using AlexaFluor 488,
AlexaFluor PE, or AlexaFluor 633 secondary antibodies at
1:1,000 dilution (Molecular Probes, Eugene, OR, USA).
Events were acquired with a FACS Canto flow cytometer
(Beckman Coulter, Fullerton, CA, USA), and data were
analyzed with FCS Express V3 software (De Novo soft-
ware, Ontario, Canada).
Karyotyping
MDPCs were subjected to G-banding analysis (Cytogenet-
ics Core Lab, University of Minnesota, USA) or spectral
karyotyping (Laboratory of Germline Modification, Van
Andel Institute, Michigan, USA).
Cytokine analysis
In vitro and in vivo cytokine concentrations were measured
by multiplex cytokine analysis, according to the manufac-
turer’s recommendations (Pierce Biotech, Rockford, IL,
USA and Cytokine Core Lab, University of Maryland,
Baltimore, MD, USA).
Trilineage differentiation of MDPC
MDPCs were cultured in eight-well chamber slides under
conditions shown to promote tissue-specific differentiation of
MAPCs into cells of all three germ cell lineages (mesoderm—
endothelium, endoderm—hepatocytes, ectoderm—neurons)
[7]. In brief, for endothelial differentiation, MDPCs were
cultured at 50,000 cells per cm2 on plastic slides coated with
Matrigel (BD Biosciences) in basal media with 10 ng/ml
VEGF. For hepatocyte differentiation, cells were cultured at
50,000 cells per cm2 on plastic slides coated with Matrigel in
MAPC basal media with 10 ng/ml fibroblast growth factor
(FGF)-4 and 20 ng/ml hepatocyte growth factor (HGF). For
neuronal differentiation, cells were cultured at 5,000 cells per
cm2 on glass slides (BD) coated with 10 ng/ml fibronectin
(BD) in Neurobasal media (Gibco) with 100 ng/ml basic
FGF (bFGF) for 7 days followed by 100 ng/ml sonic
hedgehog and 10 ng/ml FGF-8b for 7 days. All cytokines
were from R&D. After 14 days, cells were analyzed for
evidence of differentiation by real-time polymerase chain
reaction (PCR) and tissue-specific immuno-fluorescence.
Quantitative real-time PCR
After differentiation, cells were lysed within chamber slides
with lysis buffer (Stratagene, La Jolla, CA, USA), and
ribonucleic acid (RNA) was extracted using Absolutely
RNA MiniPrep Kit (Stratagene) and treated with DNase I
according to the manufacturer’s instructions. Real-time
PCR data were normalized by measuring average cycle
threshold (Ct) between candidate genes and the GAPDH
control gene. The formula 2Ct candidateð Þ

2Ct GAPDHð Þ was used
to calculate normalized ratios (NRs) for each candidate
gene. NRs were then expressed as relative expression using
the formula NRðafter differentiationÞ

NR before differentiationð Þ. As a
control, relative expression for each candidate gene was
calculated for MDPCs cultured in normal MAPC media
























Immuno-fluorescent staining of cultured cells
After differentiation, the cells were gently rinsed with PBS
and fixed with 4% para-formaldehyde for 10 min or
methanol at −20°C for 2 min. For intracellular antigens,
cells were permeabilized with 0.1% Triton-100 for 15 min.
Antibodies used were von Willebrand factor (vWF; 0082,
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Dako, Carpentaria, CA, USA), CD31 (3A12, BD Bio-
sciences), RECA1 (reca1, Abcam), albumin (A0001, Dako)
HNF-1 (H205, Santa Cruz, Santa Cruz, CA, USA),
cytokeratin 18 (Ks18.04, Chemicon), neuron-specific eno-
lase (MAB314, Chemicon), and nestin (rat401, BD Bio-
sciences). Secondary staining was then performed using
AlexaFluor 488 or AlexaFluor 594 secondary antibodies at
1:1,000 dilution (Molecular Probes). After endothelial dif-
ferentiation, the cells were incubated for 4 h with 1 μg/ml
Di-labeled acetylated low-density lipoprotein (LDL; Mo-
lecular Probes).
Assessment of limb perfusion
Perfusion was measured using fluorescent microspheres
(Molecular Probes). One million microspheres were
injected into the left ventricular cavity over 60 s. After
injection, the adductor and gastrocnemius muscles and both
kidneys were harvested and weighed. Analysis of kidney
perfusion confirmed adequate mixing within the circulation
and processing of the microspheres. Fluorescent micro-
spheres were retrieved from samples using ethanolic
alkaline digestion [19].
Histological and immuno-fluorescence analysis of hind
limb muscles
For assessment of transplanted MDPC engraftment, sam-
ples were fixed with 2% para-formaldehyde and incubated
for 12 h in X Gal reagent at 37°C. Samples were then
refixed in 10% formalin, paraffin-embedded, and cut to
5-μm sections. Sections were counterstained with nuclear
fast red. To enumerate the number of engrafted MDPCs,
ten sections from each animal (n=7) were analyzed for
presence of LacZ+ cells. The mean number of neuro-
vascular bundles (NVBs) with engrafted cells was calcu-
lated for each rat along with the mean number of cells in
each positively engrafted NVB. The following antibodies
were used: smooth muscle alpha-actin (SMA) (Sigma-
Aldrich, Clone A-2457, 1:4,000), anti-vWF (DAKO,
1:500), anti—proliferating cell nuclear antigen (PCNA;
DAKO, 1:100), anti-CD34 (Cell applications, 1:100), anti-
CD11b (Clone OX-42, BD Biosciences), or isotype control.
Secondary staining was then performed as described (see
above). To measure capillary density, samples were snap
frozen in ornithine carbamyl transferase, and 5-μm sections
were cut. Sections were stained with anti-rat CD31 (TLD
3A12, BD Biosciences) to label endothelial cells. The
number of CD31+ cells were counted from four randomly
selected fields at a magnification of ×200 from each muscle
(n=6 each group). Results were expressed as number of
CD31+ capillaries per muscle fiber. We were unable to
detect LacZ by immunohistochemistry since commercially
available antibodies against LacZ did not produce specific
staining (data not shown).
Monocyte depletion
Liposomal-encapsulated clodronate and control liposomes
were obtained from Encapsula NanoSciences LLC (Nash-
ville, TN, USA). Four hundred microliters of liposome
solution was injected via tail vein 24 h before and 48 h after
MDPC transplantation. Peripheral blood monocyte counts
were performed as previously described [20].
AMD 3100
A continuous 20 mg kg−1 week−1 dose of AMD3100
(Sigma-Aldrich) was administered to rats with the aid of an
osmotic minipump (Alzet) starting 24 h prior to ischemia.
After 2 weeks, a total dose of 40 mg had been delivered.
Statistical analysis
All results are expressed as mean±SEM. Statistical signifi-
cance was evaluated with an unpaired Student’s t test for
comparison between two groups or with analysis of
variance for comparison between multiple groups using
Prism 4 software (Graphpad Software, San Diego, CA,
USA). A probability value of p<0.05 was considered
significant.
Results
Multilineage differentiation potential of MDPCs
Previous studies have demonstrated that bone marrow may
contain stem cells with multilineage potential. We estab-
lished cultures of MDPCs from the bone marrow of Fisher
344 rats as previously described for MAPCs [7]. After over
220 population doublings (pd), the cells continued to
proliferate with a stable morphology and showed no signs
of senescence (Fig. 1a). Surface markers were assessed
by flow cytometry after 120 and 200 pd and are shown in
Fig. 1b. Costaining of MDPCs indicated that greater than
99% were copositive for CXCR4 and VEGFR1 (Fig. 1c).
In addition, MDPCs did not express Oct4 by real-time
PCR (data not shown). Despite prolonged culture, the
karyotype of MDPCs remained stable, although nonclonal
abnormalities were identified (Fig. 1d). To establish their
in vitro multipotentiality, we differentiated MDPCs into
cells with the properties of three germ cell lineages under
conditions similar to those described for the differentia-
tion of MAPCs [7]. Differentiated MDPCs expressed
markers for endodermal, neuroectodermal, and mesoder-
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mal lineages (Fig. 2). MDPCs also underwent osteogen-
esis and adipogenesis (data not shown). These data
suggest that MDPCs possess in vitro multipotentiality
similar to MAPCs yet exhibit different surface marker and
transcription factor profiles. In addition, MDPCs secrete
numerous cytokines and growth factors involved in
inflammation and angiogenesis as shown (Table 1).
MDPCs increase regional muscle perfusion and capillary
density in a hind limb model of chronic ischemia
As MDPCs have multipotent properties in vitro, we
hypothesized that MDPCs may have favorable effects in
an ischemic rat hind limb model. Twenty-four hours after
induction of ischemia, 10×106 MDPCs cultured for 120 pd
or PBS control were injected into the ischemic adductor
muscle group. In the early phase of ischemic tissue
remodeling, an increase in capillary density was observed
1 week after injury (Fig. 3a). Four weeks after MDPC
administration, relative whole-muscle perfusion was nor-
malized compared to the uninjured control leg (PBS=62±
10%, MDPC=102±14%, p<0.05; as measured per gram of
muscle; Fig. 3b).
MDPCs engraft into the neurovascular bundle of ischemic
but not normally perfused, sham-operated muscles
To track the long-term engraftment and fate of MDPCs
in vivo, MDPCs were stably transduced with a β-Gal-
expressing retrovirus. Four weeks after injection of
MDPCs, tissues were harvested and stained with X-Gal
reagent to identify LacZ-expressing cells. Significant
engraftment of MDPCs was detected when injected into
ischemic muscles (Fig. 4a). Although MDPCs were seen
Fig. 1 Characteristics of MDPCs. a Cells were enumerated at each
passage and could be maintained for over 220 pd. b MDPC surface
markers. Example of MDPCs cultured for 120 pd. MDPCs were MHC
class I, CD44, CD90 positive, and MHC class II, CD45, CD73
negative. c FACS plots of MDPCs using isotype control (left) or anti-
CXCR4 and anti-VEGFR1 antibodies (right). d Karyotype of MDPCs
at 100 and 170 pd. The majority of cells had a normal karyotype of
42XY. However, isolated nonclonal tetraploidy, translocations, or
deletions were seen. del Deletion, t translocation
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along needle tracks and occasionally scattered in between
the muscle fibers, MDPCs were predominantly localized
around the NVBs and specifically concentrated around
arterioles (Fig. 4b). Within the ischemic adductor muscles,
19±5% of NVBs were associated with LacZ+ cells. LacZ+
NVBs contained 16±7 LacZ+ cells. However, when
MDPCs were injected into normally perfused sham-
operated muscle, only the occasional cell remained after 4
weeks. Less than 1% of NVB in sham-operated mice with
normally perfused muscles had LacZ+ cells, and there were
only one to four cells associated with them (Fig. 4c). This
indicates that ischemia may provide a permissive state for
VEGFR1+ CXCR4+ MDPCs to localize and concentrate in
the NVBs.
MDPC do not differentiate into endothelial or smooth
muscle cells in ischemic muscle
LacZ+ MDPCs were mostly located in the adventitial–
medial border zone of arterioles and could not be detected
at the luminal side. Although we did not attempt to
differentiate MDPCs into smooth muscle cells in vitro, the
engraftment of MDPCs into the adventitial–medial border
of arterioles suggested that they may have adopted a
smooth muscle phenotype. Therefore, sections from
muscles harvested 4 weeks after cell injection were
counterstained with an antibody against SMA. However,
engrafted cells did not stain for SMA (Fig. 4d). In addition,
engrafted MDPCs did not stain for vWF (data not shown).
This suggests that MDPCs did not differentiate into smooth
muscle or endothelial cells. Furthermore, transplanted
MDPCs stained negative for calponin, NG2, and PDGFR-
β (data not shown), indicating, in conjunction with their
anatomical location, that they did not become pericytes.
Although MDPCs did not express CD34, engrafted cells
could be found in close proximity to adventitial CD34+
cells. Interestingly, previous reports have suggested that
Fig. 2 In vitro differentiation of MDPCs into endodermal-, neuro-
ectodermal-, and endothelial-like cells. a–c 14 days after differentia-
tion, cell lysates were analyzed by real-time PCR for tissue-specific
gene expression. a Endoderm differentiation: cytokeratin 19, 81±
21.5-fold increase over baseline, albumin, 21±2.2-fold increase, and
hepatocyte nuclear factor 1 alpha (HNF1a), 41±4.9-fold increase. b
Neuroectoderm differentiation: MAP2, 12±1.3-fold increase, NF200,
7±0.2 fold increase, and nestin, 131±9.2-fold increase. c Mesodermal
differentiation; CD31, 25±4.1-fold increase, Tie2, 85±10.0-fold
increase, and vWF, 7.2±1.9-fold increase. Yellow bars indicate cells
cultured in normal media, and blue bars indicate tissue specific
differentiation media. Asterisk, p<0.001. d–i Immuno-fluorescent
assessment of MDPCs differentiated in vitro toward d, e endodermal
lineages, stained with d anti-albumin and e anti-cytokeratin 19. f, g
Neuroectodermal lineages, stained with f anti-nestin and g anti-NSE.
h, i Endothelial-like cells, stained with h anti-RECA1 and i assessed











Table 1 In vitro cytokine levels
1226 J Mol Med (2008) 86:1221–1232
CD34+ cells located at the adventitial–medial border zone
may participate in a vascular progenitor cell niche [21].
LacZ+ skeletal muscle fibers were not observed in any
animal.
MDPCs modulate vascular remodeling through paracrine
mechanisms
Because transplanted MDPCs increased the capillary
density and perfusion of ischemic muscles but did not
differentiate into vascular structures, we examined their
ability to modulate vascular wound repair in vivo. Five and
14 days after injection of 10×106 MDPCs or PBS into
ischemic limbs, muscles were harvested, homogenized, and
submitted to cytokine analysis. At 5 days, SDF-1, mono-
cyte chemotactic protein-1 (MCP-1), and macrophage-
inflammatory protein-2 (MIP-2) levels were all found to
be significantly elevated compared to limbs injected with
PBS (Table 2). Fourteen days after transplantation, there
was no difference in cytokine levels between animals
injected with MDPCs or PBS (data not shown). This
demonstrates that MDPCs modulate local cytokine levels
during the early phase of vascular remodeling.
Importantly, local SDF-1 facilitates the retention of
CD11b+ myelo-monocytic cells at the site of wound repair.
These cells are known to be necessary for successful
balanced vascular healing [17]. Therefore, we elected to
characterize the spatial relationship between MDPCs,
infiltrating CD11b+ cells, and proliferating endothelial cells.
We performed immunohistochemistry on serial sections 1
week after injury and found that these cells shared a close
spatial relationship during the early phase of wound repair
(Fig. 5a). Next, we explored if MDPC administration with
subsequent increased local cytokine levels modulated the
number of NVB-associated CD11b+ myelo-monocytic
cells. We determined the percentage of lacZ−CD11b+ cells
at the NVBs on muscle sections of MDPC-injected animals
and compared them to PBS-injected control animals at 1
week after injury (CD11b+ cells; MDPCs=33.6±4.4% vs.
PBS=12.0±1.8%; p<0.005; Fig. 5b). By 4 weeks post-
injury, all inflammatory cell infiltrates had resolved, and
CD11b+ cells could no longer be identified (data not
shown). We suggest that in addition to endogenous
recruitment mechanisms, MDPC administration led to
increased local cytokine levels, thereby concentrating
CD11b+ cells at the NVB in the acutely ischemic tissue.
However, while SDF-1 is known to play an important role
in the localization of CD11b+ cells during vascular
remodeling, it was not clear if SDF-1 has a similar function
in the retention of transplanted MDPCs. To further explore
the mechanism leading to the localization of MDPCs at the
adventitial–medial border zone, we blocked SDF-1 function
by inhibition of its receptor CXCR4 with AMD3100, a
CXCR4-specific receptor antagonist. These experiments
revealed that the adventitial–medial border zone localiza-
tion of MDPCs requires signaling through CXCR4, as
AMD3100 virtually eliminated the retention of these cells 4
weeks after transplantation (Fig. 5c). We also observed that
in animals receiving MDPCs, AMD3100 administration led
to a decrease in the number of adventitial CD11b+ cells
(CD11b+ cells: MDPCs only=32.6±3.1%; MDPCs+
AMD3100=6.8±2.7%; p<0.0005) and a reduced number
of proliferating CD31+ endothelial cells (CD31+/BrdU+
cells [% total CD31+ cells]: MDPCs only=21.0±3.2;
MDPCs+AMD3100=11.3±1.5; p<0.05; Fig. 5d). Further-
more, in control animals that received AMD3100 without
MDPCs, we confirmed that when compared to animals
receiving MDPCs (with or without AMD3100), the known
Fig. 3 Assessment of hind limb muscle perfusion after MDPC
transplantation. a MDPCs increased capillary density of ischemic
muscle. One week after MDPC transplantation, sections were stained
for CD31. The number of CD31+ cells per muscle fiber was enumerated
and is presented as capillary/muscle fiber ratio. Asterisk, p<0.05. b
MDPCs increased perfusion of ischemic muscle. 1×106 green–yellow
fluorescent microspheres were injected into the left ventricle 4 weeks
after MDPC or PBS control transplantation. Results are expressed as
relative fluorescence of ischemic limb/fluorescence of normally per-
fused limb standardized by weight of tissue. Asterisk, p<0.05
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bone marrow-mobilizing effects of AMD3100 did not
enhance CD11b+ cell infiltration (Fig. 5d).
Finally, we undertook to determine the degree of
contribution of recruited myelo-monocytic cells to the
enhanced local cytokine levels after MDPC transplantation.
Thus, monocytes were depleted by liposomal-encapsulated
clodronate administration, and local tissue cytokine con-
centrations were determined 5 days after MDPC transplan-
tation. While monocyte depletion decreased local MIP-2
levels, we found that local levels of SDF-1 and MCP-1
were not affected (Fig. 6).
Discussion
In the present study, we investigated the effects of bone
marrow-derived MDPCs with in vitro pluripotent properties
in a hind limb model of ischemia. We demonstrated that
although MDPCs can be differentiated in vitro, they do not
differentiate in vivo into vascular cells despite engrafting
and improving perfusion. We speculate that the improve-
ment in perfusion results from the secretion of inflamma-
tory and angiogenic cytokines through paracrine
mechanisms modulating the immune response and vascular
remodeling.
Employing methods similar to those used to isolate
MAPCs [7], we isolated a mixed culture of cells that appear
to contain pluripotent progenitors. Indeed, our finding that
MDPCs (or their progeny) elaborate cytokines in the setting
of rat hind limb ischemia is entirely consistent with the
results obtained when MAPCs were administered to mice
using a similar experimental model [22]. Although, in
contrast to our study, we note that in the MAPC study, a
very limited degree of progenitor cell differentiation into
both endothelial and smooth muscle cells was also observed
Fig. 4 Fate of MDPCs after
transplantation. a, b MDPCs
engrafted into the adventitial–
medial border of arterioles in
significant numbers. Occasional
cells were also seen between
muscles fibers. a Muscle cross-
section demonstrating engraft-
ment of MDPCs. b Enlarged
view of arteriole with engrafted
MDPCs. c Very few LacZ+
MDPCs were identified after
injection into normally perfused
muscles. d MDPCs do not dif-
ferentiate into smooth muscle
cells. Sections from ischemic
hind limbs injected with
MDPCs were stained with
SMA. Despite their engraftment
at the adventitial–medial border
of arterioles, LacZ+ MDPCs
(pseudocolored green) were
negative for SMA (red), indi-
cating that they had not differ-
entiated into smooth muscle
cells. No MDPCs were found
lining the lumen of vessels. e
MDPCs and CD34+ cells (red)
were found in close proximity at
the adventitial–medial border
zone
Table 2 In vivo cytokine levels
PBS (pg/g tissue) MDPCs (pg/g tissue) Fold Δ p value
MCP-1 1,854±496 7,046±367 3.1 0.001
SDF-1 161±58 969±89 6.0 0.002
MIP-2 10.4±0.5 88±20 8.4 0.02
Gro/KC 70±19 123±58 1.8 0.44
bFGF 3,298±2041 1,663±427 0.5 0.48
HGF 797±77 616±232 0.8 0.66
VEGF 729±23 907±66 1.1 0.09
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[22]. However, we did not undertake a single-cell cloning
step as previously described for MAPCs [7] and more
recently for bone marrow stem cells [10], as we found that
in rodents, single-cell cloning tends to select for cytogenet-
ically abnormal cells. Importantly, MDPCs maintained a
stable karyotype when analyzed by G-banding or spectral
karyotyping. As we did not document any clonal abnor-
malities in MDPC cultures (defined as being present in
more than two cells), the lines were considered normal
according to the International System for Human Cytoge-
netic Nomenclature (ISCN 1995) [23].
MDPCs express MHC class I, CD44, and CD90 similar to
MSCs but do not express CD73 as described for MSCs [24].
We were able to upregulate tissue-specific antigens of the
ectoderm, endoderm, and mesoderm as measured by both
reverse transcriptase PCR and by immuno-fluorescence and
similar to the original descriptions of MAPCs and of
pMultistem recently described by Zeng et al. [9, 25].
In order to investigate the potential of MDPCs to
improve the perfusion of an ischemic tissue, we developed
a hind limb ischemia model to allow the syngeneic trans-
plantation of cells. We injected 10 million MDPCs into the
ischemic adductor muscle, a dose that is similar to previous
studies in rats [26, 27]. This led to an early but modest
increase in capillary density, with a more marked augmen-
tation in perfusion levels by 4 weeks after the ischemic
insult. We speculate that transplanted MDPCs may have
had a progressive effect during the healing process, thereby
accounting for apparently greater magnitude of enhanced
perfusion at 4 weeks, compared to the effects on capillary
density seen at 1 week.
We next studied the fate of MDPCs 4 weeks after
transplantation. MDPCs selectively engrafted into the NVB
of ischemic muscles, primarily within the adventitia of
small vessels and arterioles. Only the occasional LacZ+ cell
was detected after injection into normally perfused muscles,
indicating that MDPCs selectively engraft into ischemic
limbs. As MDPCs express the VEGF receptor VEGFR1
and the SDF-1 chemokine receptor CXCR4, we speculated
that these signaling systems may be involved in the
selective engraftment of MDPCs, in a manner similar to
the physiological engraftment of bone marrow-derived
cells. We found that inhibition of SDF-1 function with the
CXCR4-specific receptor antagonist AMD3100 inhibited
Fig. 5 MDPCs modulate the recruitment of CD11b+ mononuclear
cells to the NVBs. a Serial section staining 1 week after injury
showing the spatial relationship between CD11b+ cells, LacZ+
MDPCs, and vWF+ endothelial cells. PCNA was used as a
proliferation marker. Yellow arrowheads indicate arterioles. b Relative
numbers of CD11b+ LacZ− cells were determined at the NVBs on
MDPC-transplanted muscle sections (blue bar) and compared to
controls (yellow bar) at 1 week after injury. Asterisk, p<0.005. c Serial
section staining 4 weeks after injury revealed that recruitment and/or
retention of MDPCs to the adventitial–medial border zone was
blocked by AMD3100, an antagonist of the SDF-1 receptor CXCR4.
d One week after injury and following MDPC therapy, AMD3100
administration led to a decrease in both CD11b+ cell recruitment and
capillary density. Asterisk, p<0.05; double asterisk, p<0.0005
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the engraftment of MDPCs. Despite persistent engraftment
4 weeks after transplantation, we did not detect any MDPCs
(or their progeny) with either an endothelial or smooth
muscle cell phenotype. This would indicate that any
increase in perfusion was more likely the result of paracrine
effects rather than MDPCs forming de novo blood vessels.
It has been suggested that the media/adventitia boundary
of the vascular wall may be a source of vascular pro-
genitor cells capable of postnatal vasculogenesis [21, 28].
Since engrafted MDPCs were located in close proximity
to CD34+ cells at the adventitial–medial border zone, it
is possible that MDPCs may have selectively homed to
this niche.
In keeping with other studies of bone marrow-derived
cells [13, 22, 29–31], we demonstrated that MDPCs also
secrete multiple cytokines in vitro that are known to
modulate inflammatory and angiogenic processes. These
include members of the chemokine family, such as MCP-1
and SDF-1, as well as known angiogenic cytokines such as
VEGF, bFGF, and HGF. In a similar study, Kinnard et al.
[29] demonstrated that transplanted MSCs increase local
production of bFGF and VEGF. They also suggested that
these two factors might directly enhance endothelial and
vascular smooth muscle cell proliferation in a mouse hind
limb model. We extended this model and suggest that
transplanted cells also modulate the local inflammatory
response to injury. We demonstrated that in vivo, SDF-1,
MCP-1, and MIP-2 are increased 5 days after transplanta-
tion of MDPCs and that recruited myelo-monocytic cells
contribute to the enhanced levels of MIP-2.
SDF-1 is a chemokine that has been shown to be
transiently increased in ischemic muscles and which is
important for the homing of cells via the chemokine
receptor CXCR4 [32–34]. Local VEGF production in
ischemic tissues is believed to be the key cytokine
controlling SDF-1 release [17, 18]. Vascular myofibroblasts
secrete VEGF, which subsequently induces the expression
of SDF-1. VEGF recruits circulating bone marrow-derived
cells, predominantly myeloid mononuclear cells, which are
then retained in close proximity to angiogenic vessels.
Retention is mediated via the chemokine receptor CXCR4
interacting with locally produced SDF-1. These retained
myeloid cells then enhance the local proliferation of
endothelial cells via the secretion of proangiogenic cyto-
kines [17]. Several studies have shown that the recruitment
of monocytes to ischemic tissues, without incorporation or
differentiation into vascular lineages, plays an important
role in angiogenesis [35, 36]. Increasing SDF-1 expression
in ischemic tissues with cell transplantation is likely to
augment the physiological recruitment, homing, and trap-
ping of bone marrow-derived cells, as will increasing MCP-
1 expression [37]. The recruitment of myeloid cells by
MDPCs is likely to further improve perfusion via the
stimulation of local endothelial cells [17, 18]. We found
that ischemic muscles produced elevated levels of SDF-1
and VEGF. As MDPCs also express VEGFR1 and CXCR4,
the recruitment and retention of MDPCs to the adventitial–
medial border zone of blood vessels may also be mediated
via the VEGF–SDF-1 system in a manner similar to the
recruitment of myeloid cells [13, 17]. Indeed, inhibition of
Fig. 6 Monocyte depletion
decreases MIP-2 levels after
MDPC transplantation in the rat
ischemic hind limb. a Mono-
cytes were significantly depleted
by administration of liposomal
encapsulated clodronate (trian-
gles) compared to control lip-
osomes (squares) during the
first 6 days after induction of
hind limb ischemia. LI liposome
injection; triple asterisk, p<
0.0001. b Local tissue cytokine
concentrations were determined
5 days after MDPC transplanta-
tion. Monocyte depletion (depl)
significantly decreased local
MIP-2 levels in ischemic hind
limbs compared to controls
(Co). Monocyte depletion did
not influence local SDF-1 or
MCP-1 levels. Double asterisk,
p<0.001
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SDF-1/CXCR4 function by AMD3100, a CXCR4-specific
receptor antagonist, dramatically reduced vascular MDPC
retention.
In summary, our findings indicate that MDPCs may be
recruited to the adventitial–medial border zone of vessels
within ischemic tissue by VEGF and/or SDF-1. Increased
levels of SDF-1 and other cytokines/chemokines then trap
additional CD11b+ mononuclear cells at the site of tissue
repair. The augmented inflammatory response to ischemic
tissue damage enhances capillary density and tissue
perfusion. An understanding of these complex interactions
between transplanted, local inflammatory, and vascular
cells constitutes a critical platform for the successful
implementation of clinical cell therapy.
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